Laboratory Corporation of America Holdings (NYSE:LH)‘s stock had its “overweight” rating reiterated by research analysts at Barclays PLC in a research report issued on Monday. They currently have a $182.00 price objective on the medical research company’s stock, up from their prior price objective of $175.00. Barclays PLC’s price objective suggests a potential upside of 18.43% from the stock’s current price.

A number of other analysts have also recently commented on LH. Zacks Investment Research cut Laboratory Corporation of America Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, April 19th. Jefferies Group LLC lowered their price target on Laboratory Corporation of America Holdings from $159.00 to $157.00 and set a “hold” rating for the company in a research note on Friday, April 28th. Credit Suisse Group reaffirmed a “buy” rating and issued a $146.00 price target on shares of Laboratory Corporation of America Holdings in a research note on Sunday, May 28th. ValuEngine cut Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Saturday, June 3rd. Finally, BidaskClub cut Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $154.88.

Shares of Laboratory Corporation of America Holdings (NYSE LH) traded up 0.25% on Monday, hitting $153.68. 291,570 shares of the company’s stock traded hands. Laboratory Corporation of America Holdings has a 1-year low of $119.51 and a 1-year high of $154.82. The firm’s 50-day moving average price is $142.43 and its 200 day moving average price is $138.87. The company has a market cap of $15.72 billion, a price-to-earnings ratio of 21.11 and a beta of 0.93.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings results on Tuesday, April 25th. The medical research company reported $2.22 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.03. The company had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Laboratory Corporation of America Holdings had a return on equity of 16.99% and a net margin of 7.76%. Laboratory Corporation of America Holdings’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.02 EPS. On average, equities research analysts expect that Laboratory Corporation of America Holdings will post $9.43 earnings per share for the current year.

WARNING: This piece was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/07/17/barclays-plc-reaffirms-overweight-rating-for-laboratory-corporation-of-america-holdings-lh.html.

In other news, Director Jean-Luc Belingard sold 992 shares of the stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $142.19, for a total value of $141,052.48. Following the completion of the sale, the director now owns 32,935 shares of the company’s stock, valued at approximately $4,683,027.65. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Lance Berberian sold 3,613 shares of the stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $139.84, for a total value of $505,241.92. Following the completion of the sale, the senior vice president now directly owns 5,789 shares of the company’s stock, valued at approximately $809,533.76. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Parallel Advisors LLC boosted its stake in Laboratory Corporation of America Holdings by 377.7% in the first quarter. Parallel Advisors LLC now owns 1,261 shares of the medical research company’s stock worth $177,000 after buying an additional 997 shares during the period. TNB Financial acquired a new stake in Laboratory Corporation of America Holdings during the second quarter worth $208,000. Union Bankshares Corp acquired a new stake in Laboratory Corporation of America Holdings during the second quarter worth $211,000. Indiana Trust & Investment Management CO acquired a new stake in Laboratory Corporation of America Holdings during the first quarter worth $202,000. Finally, Ingalls & Snyder LLC acquired a new stake in Laboratory Corporation of America Holdings during the first quarter worth $206,000. Institutional investors and hedge funds own 91.09% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.